Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INJECTAPAP vs AZO GANTRISIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Sulfamethoxazole is a competitive inhibitor of dihydropteroate synthase, blocking bacterial folic acid synthesis. Phenazopyridine is an azo dye with local analgesic effects on urinary tract mucosa.
Management of mild to moderate pain,Reduction of fever
Urinary tract infections,Pain relief associated with lower urinary tract irritation,Pyelonephritis
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
AZO GANTRISIN (phenazopyridine 100 mg / sulfisoxazole 500 mg): 2 tablets orally 4 times daily for 2 days, then 1 tablet 4 times daily for up to 5 days.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Sulfamethoxazole: 9-12 hours (adults with normal renal function), prolonged to 20-50 hours in renal impairment; trimethoprim component: 8-11 hours. Clinical context: dosing interval adjusted based on Cr Cl.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Sulfamethoxazole is metabolized primarily via N-acetylation in the liver; phenazopyridine undergoes hepatic metabolism.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Renal: 70-100% (sulfamethoxazole and metabolites; 15-30% as unchanged drug; remainder as acetylated and glucuronide conjugates). Biliary/fecal: <3%.
10-25% bound to albumin at therapeutic concentrations.
Sulfamethoxazole: 65-70% bound to albumin; trimethoprim: 40-45% bound to albumin.
0.8-1.0 L/kg; suggests distribution into total body water.
Sulfamethoxazole: 0.2-0.3 L/kg (reflects distribution into extracellular fluid, not extensively tissue-bound); trimethoprim: 1-2 L/kg (higher due to lipophilicity, penetrates tissues including prostate and CSF). Clinical meaning: higher Vd of trimethoprim contributes to effective tissue concentrations.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
Oral: 85-95% for both components (tablets); suspension: ~90%.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Cr Cl 50-80 m L/min: 1 tablet 3-4 times daily; Cr Cl 10-49 m L/min: 1 tablet 2-3 times daily; Cr Cl <10 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Children 6-12 years: 0.5-1.5 teaspoons (2.5-7.5 m L) of suspension (equivalent to 75-225 mg sulfisoxazole and 15-45 mg phenazopyridine) orally 4 times daily; children >12 years: adult dose.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Initiate at lower doses (e.g., 1 tablet 3 times daily) and monitor for renal function and CNS side effects; contraindicated if Cr Cl <50 m L/min.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Sulfonamides have been associated with severe reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Fatalities have occurred.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Risk of severe hypersensitivity reactions, blood dyscrasias, hepatotoxicity, and renal impairment. Use caution in patients with G6PD deficiency, hepatic impairment, or renal insufficiency. Phenazopyridine may cause orange-red discoloration of urine.
Hypersensitivity to acetaminophen or any component of the formulation
Hypersensitivity to sulfonamides or phenazopyridine; severe hepatic or renal impairment; porphyria; G6PD deficiency; pregnancy at term; lactation; children < 12 years (due to phenazopyridine component).
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Avoid acidic foods and beverages (e.g., citrus fruits, tomatoes, cola) as they may decrease the efficacy of sulfisoxazole by increasing urine acidity, which can reduce solubility and increase risk of crystalluria. Maintain adequate fluid intake; avoid alcohol. No other significant food interactions.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Pregnancy Category D. First trimester: Associated with neural tube defects, cardiovascular anomalies, and oral clefts due to antifolate effect of trimethoprim. Second and third trimesters: Risk of kernicterus in newborn due to sulfonamide displacement of bilirubin from albumin, especially near term. Avoid use during pregnancy unless benefit outweighs risk.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
Sulfamethoxazole and trimethoprim are excreted into breast milk; M/P ratio not established. Avoid in nursing mothers with infants under 2 months of age due to risk of kernicterus. In older infants, caution if infant has G6PD deficiency or hyperbilirubinemia.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
No standard dose adjustment recommended for pregnancy; however, caution due to increased volume of distribution and renal clearance. Monitor for therapeutic efficacy and toxicity. Consider folate supplementation (5 mg folic acid daily) to mitigate antifolate effects.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
AZO GANTRISIN combines phenazopyridine (urinary analgesic) and sulfisoxazole (sulfonamide antibiotic). Phenazopyridine imparts a red-orange color to urine and may stain contact lenses. Sulfisoxazole is contraindicated in infants <2 months due to risk of kernicterus. Use with caution in patients with G6PD deficiency, sulfonamide allergy, or renal impairment. Monitor for crystalluria; ensure adequate hydration. Avoid concurrent use with methenamine due to increased risk of crystalluria.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
Take this medication with a full glass of water and drink plenty of fluids throughout the day to prevent kidney stones.,Your urine may turn red-orange; this is harmless but may stain clothing or contact lenses.,Do not use for longer than 2 days unless directed by your doctor, as it only treats symptoms of UTI, not the infection.,Complete the full course of the sulfisoxazole component even if you feel better.,Avoid prolonged sun exposure; sulfonamides may cause photosensitivity. Use sunscreen.,Seek immediate medical attention if you develop skin rash, sore throat, fever, unusual bleeding, or bruising.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INJECTAPAP vs AZO GANTRISIN, answered by our medical review team.
INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. AZO GANTRISIN is a Sulfonamide Antibiotic that works by Sulfamethoxazole is a competitive inhibitor of dihydropteroate synthase, blocking bacterial folic acid synthesis. Phenazopyridine is an azo dye with local analgesic effects on urinary tract mucosa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INJECTAPAP and AZO GANTRISIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. The standard adult dose of AZO GANTRISIN is: AZO GANTRISIN (phenazopyridine 100 mg / sulfisoxazole 500 mg): 2 tablets orally 4 times daily for 2 days, then 1 tablet 4 times daily for up to 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INJECTAPAP and AZO GANTRISIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. AZO GANTRISIN is classified as Category C. Pregnancy Category D. First trimester: Associated with neural tube defects, cardiovascular anomalies, and oral clefts due to antifolate effect of trimethoprim. Second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.